Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.